• Japanese
  • Korean
  • Chinese
Cover Image

What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)

Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline.This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market?

The following target areas are covered in the report:

  • Acne
  • Addiction
  • Allergy
  • Alzheimer's Disease
  • Anthrax
  • Asthma
  • Campylobacter Infection
  • Chlamydia
  • Croup
  • Cytomegalovirus (CMV)
  • Dengue Fever
  • Diabetes
  • Ebola
  • Epstein-Barr Virus
  • Enterotoxigenic Escherichia coli (ETEC)
  • Heart Attack
  • Helicobacter Pylori
  • Hepatitis
  • Herpesvirus
  • Hookworm
  • Hypertension
  • HIV/AIDS
  • Leishmaniasis
  • Malaria
  • MRSA Infection
  • Multiple Sclerosis
  • Obesity
  • Parainfluenza Virus Type 3
  • Parkinson's Disease
  • Plague
  • Ross River Virus
  • Shigellosis
  • Stroke
  • Tuberculosis
  • West Nile Virus

For each of these areas the report provides Mortality, Severity and Treatment Availability ratings. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Kalorama Information has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Recent Project Terminations, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process.

In addition, the report focuses on the emerging vaccine activities of the following companies:

  • Affiris
  • Alk-Abello A/S
  • Allergy Therapeutics
  • AstraZeneca
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Crucell
  • Cytos Biotechnology
  • GlaxoSmithKline
  • Hawaii Biotech
  • Merck & Co. Inc
  • Mymetics
  • Nabi Biopharmaceuticals
  • Novartis
  • Opexa Therapeutics
  • Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2021. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Emerging Vaccines
    • Scope and Methodology
    • Overview
    • Emerging Vaccines and Forecasts
    • The Global Market for Emerging Vaccines

CHAPTER TWO: INTRODUCTION TO VACCINES

  • A Brief History: The Development of Vaccines
  • The Immune Response
  • Mechanism of Action
  • Types of Vaccines
    • Attenuated (Weakened) Live Viruses
    • Killed (Inactivated) Viruses
    • Toxoid Vaccines
    • Genetically Engineered/Modified Vaccines
    • Bacteria-Based Vaccines
  • Vaccine Approval Process
  • Refusal to Immunize
  • Expanding Vaccine Availability
  • Other Trends Driving the Vaccines Market

CHAPTER THREE: EMERGING VACCINES

  • Introduction
  • Emerging Vaccines by Disease Area
    • Acne
    • Addiction
    • Allergy
    • Alzheimer's Disease
    • Anthrax
    • Asthma
    • Campylobacter Infection
    • Chlamydia
    • Croup
    • Cytomegalovirus (CMV)
    • Dengue Fever
    • Diabetes
    • Ebola
    • Epstein-Barr Virus
    • Enterotoxigenic Escherichia coli (ETEC
    • Heart Attack
    • Helicobacter Pylori
    • Hepatitis
    • Herpesvirus
    • Hookworm
    • Hypertension
    • HIV/AIDS
    • Leishmaniasis
    • Malaria
    • MRSA Infection
    • Multiple Sclerosis
    • Obesity
    • Parainfluenza Virus Type 3
    • Parkinson's Disease
    • Plague
    • Ross River Virus
    • Shigellosis
    • Stroke
    • Tuberculosis
    • West Nile Virus

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST

  • the Global Market for Emerging Vaccines
  • Emerging Vaccines Market Segment Forecasts
    • Acne
    • Addiction
    • Allergies
    • Alzheimer's Disease
    • Anthrax
    • Asthma
    • Campylobacter Infection
    • Celiac Disease
    • Chlamydia
    • Croup
    • Diabetes
    • Ebola
    • EBV Infection
    • ETEC Infection
    • Heart Attack
    • H. Pylori Infection
    • Hepatitis C and E
    • Herpesvirus Infection
    • Hookworm
    • Hypertension
    • HIV/AIDS
    • Leishmaniasis
    • Malaria
    • MRSA Infection
    • Multiple Sclerosis
    • Obesity
    • PIV-3 Infection
    • Parkinson's Disease
    • Plague
    • RSV Infection
    • Ross River Virus Infection
    • Shigellosis
    • Stroke
    • Tuberculosis
    • West Nile Virus

CHAPTER FIVE: ISSUES AND TRENDS

  • New Vaccine Delivery System
    • Edible Vaccines
    • Mucosal Delivery
    • Intranasal Delivery
    • Vaccine Patches
  • Funding Shortfalls
  • Project Terminations

CHAPTER SIX: COMPANY PROFILES

  • Affiris
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Alk-Abello A/S
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Allergy Therapeutics
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • AstraZeneca
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Bavarian Nordic A/S
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Baxter Healthcare
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Crucell
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Cytos Biotechnology
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial
  • GlaxoSmithKline
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Hawaii Biotech
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Merck & Co., Inc.
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Mymetics
    • History and Lines of Business
    • Emerging Vaccine Products
    • Financial Information
  • Nabi Biopharmaceuticals
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Novartis
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Opexa Therapeutics
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information
  • Sanofi Pasteur
    • History and Lines of Business
    • Emerging Vaccine Activities
    • Financial Information

APPENDIX: COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: Status of Emerging Vaccines by Disease

CHAPTER TWO: INTRODUCTION TO VACCINES

  • Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011
  • Table 2-2: Vaccine-Preventable Diseases, December 2011
  • Figure 2-1: Attenuated Virus Production
  • Table 2-3: VAERS Table of Reportable Events Following Vaccination

CHAPTER THREE: EMERGING VACCINES

  • Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines, 2012
  • Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines
  • Table 3-1: Emerging Vaccines by Disease and Stage of Testing
  • Figure 3-3: Comparative Severity Ranking of Acne
  • Figure 3-4: Comparative Severity Ranking of Addiction
  • Figure 3-5: Comparative Severity Ranking of Allergy
  • Figure 3-6: Comparative Severity Ranking of Alzheimer's Disease
  • Figure 3-7: Comparative Severity Ranking of Anthrax
  • Figure 3-8: Comparative Severity Ranking of Asthma
  • Figure 3-9: Comparative Severity Ranking of Campylobacter Infection
  • Figure 3-10: Comparative Severity Ranking of Celiac Disease
  • Figure 3-11: Comparative Severity Ranking of Chlamydia
  • Figure 3-12: Comparative Severity Ranking of Croup
  • Figure 3-13: Comparative Severity Ranking of Cytomegalovirus
  • Figure 3-14: Comparative Severity Ranking of Dengue Fever
  • Figure 3-15: Comparative Severity Ranking of Diabetes
  • Figure 3-16: Comparative Severity Ranking of Ebola
  • Figure 3-17: Comparative Severity Ranking of EBV
  • Figure 3-18: Comparative Severity Ranking of ETEC
  • Figure 3-19: Comparative Severity Ranking of Heart Attack
  • Figure 3-20: Comparative Severity Ranking of H. Pylori Infection
  • Figure 3-21: Comparative Severity Ranking of Hepatitis C and E
  • Figure 3-22: Comparative Severity Ranking of Herpesvirus Infection
  • Figure 3-23: Comparative Severity Ranking of Hookworm
  • Figure 3-24Comparative Severity Ranking of Hypertension
  • Figure 3-25: Comparative Severity Ranking of HIV/AIDS
  • Figure 3-26: Comparative Severity Ranking of Leishmaniasis
  • Figure 3-27: Comparative Severity Ranking of Malaria
  • Figure 3-28: Comparative Severity Ranking of MRSA Infection
  • Figure 3-29: Comparative Severity Ranking of Multiple Sclerosis
  • Figure 3-30: Comparative Severity Ranking of Obesity
  • Figure 3-31: Comparative Severity Ranking of PIV-3 Infection
  • Figure 3-32: Comparative Severity Ranking of Parkinson's Disease
  • Figure 3-33: Comparative Severity Ranking of Plague
  • Figure 3-34: Comparative Severity Ranking of RSV Infection
  • Figure 3-35: Comparative Severity Ranking of Ross River Virus Infection
  • Figure 3-36: Comparative Severity Ranking of Shigellosis
  • Figure 3-37: Comparative Severity Ranking of Stroke
  • Figure 3-38: Comparative Severity Ranking of Tuberculosis
  • Figure 3-39: Comparative Severity Ranking of West Nile Virus Infection

CHAPTER FOUR: MARKET ANALYSIS

  • Table 4-1:World Market for Emerging Vaccines by Type, 2011
  • Table 4-2: World Market for Emerging Vaccines by Type, 2011-2021
  • Table 4-3: World Acne Vaccine Market 2011-2021
  • Table 4-4: World Addiction Vaccine Market 2011-2021
  • Table 4-5: World Allergy Vaccine Market 2011-2021
  • Table 4-6: World Alzheimer's Disease Vaccine Market 2011-2021
  • Table 4-7: World Anthrax Vaccine Market 2011-2021
  • Table 4-8: World Asthma Vaccine Market 2011-2021
  • Table 4-9: World Campylobacter Vaccine Market 2011-2021
  • Table 4-10: World Celiac Disease Vaccine Market 2011-2021
  • Table 4-11: World Chlamydia Vaccine Market 2011-2021
  • Table 4-12: World Croup Vaccine Market 2011-2021
  • Table 4-13: World Cytomegalovirus Vaccine Market 2011-2021
  • Table 4-14: World Dengue Fever Vaccine Market 2011-2021
  • Table 4-15: World Diabetes Vaccine Market 2011-2021
  • Table 4-16: World Ebola Vaccine Market 2011-2021
  • Table 4-17: World EBV Vaccine Market 2011-2021
  • Table 4-18: World ETEC Vaccine Market 2011-2021
  • Table 4-19: World Heart Attack Vaccine Market 2011-2021
  • Table 4-20: World H. Pylori Vaccine Market 2011-2021
  • Table 4-21: World Hepatitis C & E Vaccine Market 2011-2021
  • Table 4-22: World Herpesvirus Vaccine Market 2011-2021
  • Table 4-23: World Hookworm Vaccine Market 2011-2021
  • Table 4-24: World Hypertension Vaccine Market 2011-2021
  • Table 4-25: World HIV/AIDS Vaccine Market 2011-2021
  • Table 4-26: World Leishmaniasis Vaccine Market 2011-2021
  • Table 4-27: World Malaria Vaccine Market 2011-2021
  • Table 4-28: World MRSA Vaccine Market 2011-2021
  • Table 4-29: World Multiple Sclerosis Vaccine Market 2011-2021
  • Table 4-30: World Obesity Vaccine Market 2011-2021
  • Table 4-31: World PIV-3 Vaccine Market 2011-2021
  • Table 4-32: World Parkinson's Disease Vaccine Market 2011-2021
  • Table 4-33: World Plague Vaccine Market 2011-2021
  • Table 4-34: World RSV Vaccine Market 2011-2021
  • Table 4-35: World Ross River Virus Vaccine Market 2011-2021
  • Table 4-36: World Shigellosis Vaccine Market 2011-2021
  • Table 4-37: World Stroke Vaccine Market 2011-2021
  • Table 4-38: World Tuberculosis Vaccine Market 2011-2021
  • Table 4-39: World West Nile Virus Vaccine Market 2011-2021
Show More
Pricing